Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

initially, and an additional cohort of patients with relapsed/ refractory disease treated with 840mg daily was enrolled following closure of the 420mg qD relapsed/ refractory cohort. This group of patients had a shorter median follow-up time and were included only for initial response assessment and summary safety data.

Overall, PCI-32765 has been well-tolerated; discontinuation of treatment for adverse events occurred in only 3 of 83 patients. Diarrhea, nausea/ vomiting, and dyspepsia were the most frequently reported events and were typically of modest severity. Significant neutropenia and thrombocytopenia were uncommon in the 420mg qD cohorts, but more frequently observed (18%, 9% respectively) in the 840mg qD cohort in spite of the shorter follow-up. As previously reported, a characteristic pattern of response occurred in the CLL patients, with rapid reduction of lymph node disease and a corresponding initial phase of lymphocytosis. The resolution of lymphocytosis was more rapid in treatment-naive versus relapsed/ refractory patients, corresponding to a more rapid evolution of overall response per standard criteria in treatment-naive patients. At a median follow-up of 6.3 months, 67% of patients with treatment-naive disease had achieved an overall response by standard criteria, with an additional 19% of patients achieving a nodal response. At a median follow-up of 7.8 months in the cohort of relapsed/ refractory patients treated with 420mg qD, the rate of overall objective response was 48% with an additional 41% of patients having achieved a nodal response. The initial response assessment at 2 months in patients with relapsed/ refractory disease appeared similar between the 420mg qD and 840mg qD doses. Additionally, achieving response appeared to be independent of poor-risk features, such as del (17p), del (11q), and lack of mutation in the immunoglobulin heavy chain variable region gene. To date, only three patients have experienced disease progression,
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)...  In today,s ever-changing marketplace, call centers must meet ... connected, and increasingly impatient with slow service. The need ... and tools is driving call centers to explore new ... According to research by benchmarking firm, Best Practices, LLC, ... a call center study realize the impact of social ...
(Date:7/31/2015)... RnRMarketResearch.com adds Syringes and ... that provides an overview of syringes and needles ... in-house databases, secondary and primary research. ... pipeline spread across 124 pages, talking about 13 ... 5 figures is now available at http://www.rnrmarketresearch.com/syringes-and-needles-pipeline-review-2015-market-report.html ...
(Date:7/31/2015)... , July 31, 2015  Xcelience, a ... that it has made a structured cash investment ... company specializing in milling, micronization and powder size ... help grow Powdersize,s business while simultaneously adding a ... Xcelience,s portfolio of capabilities. "As ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3
... June 21 Thomson Reuters announced today that it has ... change the way biotechnology, pharmaceutical and academic organizations find partnering opportunities ... , ... organizations with drugs in development. It enables authorized users to share ...
... , June 18 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese,Medicines Company ... leading,specialty pharmaceutical company focusing on the development, manufacturing,marketing and selling ... its financial results for the quarter ended March 31, ... the Quarter Ended March 31, 2010, -- ...
Cached Medicine Technology:Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 2Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 3Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 2Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 3Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 4Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 5Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 6Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 7Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 8Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 9Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 10Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 11Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 12Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 13Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 14Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 15
(Date:8/1/2015)... ... 2015 , ... Have you ever wondered what “Karma” really means? Does it even exist? Can ... , Vedic tradition, which gave birth to Hinduism, is one of the most ancient spiritual ... this tradition. According to the wisdom of this heritage, Karma is a very real and ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked over ... was greeted by friends and family. He visited CCAR and left an inspirational message ...
(Date:7/31/2015)... CA (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 will ... National Football League’s biggest day each year is the Super Bowl. In the two weeks ... takes place from the host venue. The 2016 Super Bowl game will mark the 50th ...
(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
Breaking Medicine News(10 mins):Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3
... unusual metals could form an effective treatment against colon and ... other drugs, according to research at the University of Warwick ... in the Journal of Medicinal Chemistry , showed that ... and Osmium, which are found in the same part of ...
... Macrophages, the scavenger cells of the body,s immune ... University School of Medicine researchers have identified one pathway ... causes a lupuslike autoimmune disease. The findings could ... of lupus in humans and potential drug treatments for ...
... other risks await, experts warn, , SUNDAY, Oct. 18 (HealthDay ... week -- a new study emerges touting the health benefits ... a pint of dark beer. , The benefits related to ... for instance, found that moderate alcohol consumption reduces the risk ...
... younger the child, the more likely the pain, says research led ... who play video games for more than an hour a day ... study has found. , The lead author of the study knows ... the idea to study joint pain among his classmates at Rossman ...
... , DES MOINES, Iowa, Oct. 16 The announcement by the ... to determine if three pigs from the Minnesota State Fair in ... in the U.S. swine herd provides an opportunity to stress three ... you cannot get the H1N1 flu from eating pork. Pork and ...
... WALTHAM, Mass., Oct. 16 Augmenix announced today that it ... round was led by Ascension Health Ventures (AHV) in St. ... and Pinnacle Ventures. Also participating were Catalyst Health Ventures ... radiation oncology has traditionally been of a large capital equipment ...
Cached Medicine News:Health News:Metals could forge new cancer drug 2Health News:Stanford study identifies cellular mechanism that causes lupuslike symptoms in mice 2Health News:Stanford study identifies cellular mechanism that causes lupuslike symptoms in mice 3Health News:Drinking Your Way to Health? Perhaps Not 2Health News:Drinking Your Way to Health? Perhaps Not 3Health News:Video Games Can Play Havoc With Kids' Joints 2Health News:Video Games Can Play Havoc With Kids' Joints 3Health News:Augmenix, Inc. Closes $6.1 Million Financing 2
Double-ended. 4 mm x 4 mm round end and 3 mm spatula end. Designated most popular model or size....
4 mm wide tip....
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
2.5 mm x 4 mm opening. Hexagonal handle....
Medicine Products: